Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...

Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...

Moderna stock remains under pressure with analysts projecting steep losses in the fourth quarter. Is MRNA stock a sell in ...

Shares of Moderna Inc. MRNA slipped 2.31% to $41.83 Friday, on what proved to be an all-around mixed trading session for the ...

Moderna's (NASDAQ:MRNA) mRNA-1647, its vaccine asset for cytomegalovirus (CMV), may not yield positive interim phase 3 data ...

Analysts issued an Underperform rating for shares while reluanching coverage of large-cap U.S. pharma and biotech names.

Shares of Moderna Inc. MRNA sank 0.09% to $42.82 Thursday, on what proved to be an all-around dismal trading session for the ...

MicroStrategy Inc, the dot-com-era software maker whose metamorphosis into a leveraged bet on bitcoin has transfixed Wall ...

In the chaotic early days of the pandemic, Wall Street scrambled to place bets on the companies that looked the most likely to thrive the uncharted waters that were rising all around us. The early ...

The advisory committee, which met at the FDA’s request Thursday, did not reach a conclusion about the cause of a safety ...

Palantir, MicroStrategy, and Axon Enterprise are set to join the Nasdaq 100 Index on Monday, Dec. 23, replacing Super Micro ...